Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Arvinas announced three poster presentations for vepdegestrant at the 2024 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant, a PROTAC estrogen receptor degrader, is being jointly developed with Pfizer for treating ER+/HER2- breast cancer. The presentations will cover: combination therapy with palbociclib in CDK4/6 inhibitor-resistant models, preliminary Phase 1b results of vepdegestrant plus abemaciclib in advanced breast cancer, and CYP3A4-mediated drug interaction risks when combined with CDK4/6 inhibitors and everolimus. The posters will be presented on December 12, 2024.
Arvinas ha annunciato tre presentazioni di poster per vepdegestrant al Simposio di San Antonio sul Cancro al Seno 2024 (SABCS). Vepdegestrant, un degradatore del recettore estrogenico PROTAC, è in fase di sviluppo congiunto con Pfizer per il trattamento del cancro al seno ER+/HER2-. Le presentazioni copriranno: terapia combinata con palbociclib in modelli resistenti agli inibitori CDK4/6, risultati preliminari della Fase 1b di vepdegestrant più abemaciclib nel cancro al seno avanzato, e rischi di interazione farmacologica mediati da CYP3A4 quando combinati con inibitori CDK4/6 ed everolimus. I poster saranno presentati il 12 dicembre 2024.
Arvinas anunció tres presentaciones de pósteres para vepdegestrant en el Simposium de Cáncer de Mama de San Antonio 2024 (SABCS). Vepdegestrant, un degradador de receptor de estrógeno PROTAC, se está desarrollando conjuntamente con Pfizer para tratar el cáncer de mama ER+/HER2-. Las presentaciones cubrirán: terapia combinada con palbociclib en modelos resistentes a inhibidores de CDK4/6, resultados preliminares de la Fase 1b de vepdegestrant más abemaciclib en cáncer de mama avanzado, y riesgos de interacción medicamentosa mediada por CYP3A4 cuando se combina con inhibidores de CDK4/6 y everolimus. Los pósteres se presentarán el 12 de diciembre de 2024.
Arvinas는 2024년 샌안토니오 유방암 심포지엄(SABCS)에서 vepdegestrant에 대한 세 개의 포스터 발표를 발표했습니다. Vepdegestrant는 PROTAC 에스트로겐 수용체 분해제로, ER+/HER2- 유방암 치료를 위해 Pfizer와 공동 개발되고 있습니다. 발표 내용은 CDK4/6 억제제에 저항성을 가진 모델에서의 팔보시클립과의 병용 요법, 고급 유방암에서의 vepdegestrant와 아베마시클립의 1상 1b 결과, CDK4/6 억제제 및 에베롤리무스와의 병용 시 CYP3A4 매개 약물 상호작용 위험에 대해 다룰 것입니다. 포스터는 2024년 12월 12일에 발표될 예정입니다.
Arvinas a annoncé trois présentations d’affiches pour vepdegestrant lors du Symposium de San Antonio sur le cancer du sein 2024 (SABCS). Vepdegestrant, un dégradateur de récepteur d’œstrogène PROTAC, est développé conjointement avec Pfizer pour traiter le cancer du sein ER+/HER2-. Les présentations porteront sur : l’association du traitement avec palbociclib dans des modèles résistants aux inhibiteurs de CDK4/6, les résultats préliminaires de la phase 1b de vepdegestrant plus abemaciclib dans le cancer du sein avancé, et les risques d’interaction médicamenteuse médiés par CYP3A4 lorsque combinés avec des inhibiteurs de CDK4/6 et everolimus. Les affiches seront présentées le 12 décembre 2024.
Arvinas hat drei Posterpräsentationen für vepdegestrant auf dem San Antonio Breast Cancer Symposium 2024 (SABCS) angekündigt. Vepdegestrant, ein PROTAC-Östrogenrezeptor-Degrader, wird gemeinsam mit Pfizer zur Behandlung von ER+/HER2- Brustkrebs entwickelt. Die Präsentationen werden Folgendes umfassen: Kombinationstherapie mit Palbociclib in CDK4/6-hemmungsresistenten Modellen, vorläufige Ergebnisse der Phase 1b von vepdegestrant plus Abemaciclib bei fortgeschrittenem Brustkrebs und Risiken von Arzneimittelwechselwirkungen, die durch CYP3A4 vermittelt werden, wenn sie mit CDK4/6-Inhibitoren und Everolimus kombiniert werden. Die Poster werden am 12. Dezember 2024 präsentiert.
Positive
- Joint development partnership with Pfizer enhances commercialization potential
- Multiple clinical development programs advancing simultaneously
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), being held December 10-13, 2024, in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic estrogen receptor positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Poster session details are as follows:
Poster Title: Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, Plus Palbociclib in CDK4/6 Inhibitor-Resistant WT ER and ER Y537S Mutant Patient Derived Xenograft (PDX) Models
Poster Session 3 (ID: P3-01-16)
Date: Thursday, December 12
Time: 12:30 p.m. – 2:00 p.m. CT
Poster Title: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results
Poster Session 4 (ID: P4-12-03)
Date: Thursday, December 12
Time: 5:30 p.m. – 7:00 p.m. CT
Poster Title: Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination with Cyclin Dependent Kinase (CDK)4/6 Inhibitors and Everolimus
Poster Session 4 (ID: P4-08-13)
Date: Thursday, December 12
Time: 5:30 p.m. – 7:00 p.m. CT
For copies of the abstracts, please visit the official SABCS website here.
About Vepdegestrant
Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer.
In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits.
The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential of vepdegestrant as a monotherapy and as part of combination therapy to potentially treat patients with ER+/HER2- metastatic breast cancer. Statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas’ and Pfizer’s performance of the respective obligations with respect to Arvinas’ collaboration with Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant on current timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
What will Arvinas (ARVN) present at SABCS 2024?
Arvinas will present three posters about vepdegestrant, including clinical data and drug interaction studies, at SABCS on December 12, 2024.
What is the purpose of Arvinas’ (ARVN) vepdegestrant treatment?
Vepdegestrant is being developed for treating patients with early and locally advanced or metastatic ER+/HER2- breast cancer.
Who is Arvinas (ARVN) partnering with to develop vepdegestrant?
Arvinas is jointly developing vepdegestrant with Pfizer for breast cancer treatment.
What clinical trial results will Arvinas (ARVN) present for vepdegestrant?
Arvinas will present preliminary Phase 1b results from the TACTIVE-U trial studying vepdegestrant plus abemaciclib in ER+/HER2- advanced or metastatic breast cancer.
